1. Finland Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Revenio Group Oyj

Revenio Group Oyj

11.08
EUR
+0.12
(+1.09%)
0.42EPS
24.13P/E
272.28MMarket Cap
Nov 12Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.58
0.68
0.85
0.98
1.12
1.28
1.93
2.3
2.97
3.65
3.63
3.89
4.12
4.51
Basic EPS, GAAP
0.19
-0.03
0.27
0.23
0.29
0.34
0.36
0.5
0.65
0.82
0.72
0.7
0.65
0.42
Free Cash Flow per Basic Share
0.2
0.06
0.22
0.19
0.29
0.36
0.43
0.51
0.73
0.8
0.26
0.74
0.98
0.42
Dividend per Share
0.21
0.1
0.15
0.23
0.25
0.26
0.26
0.3
0.32
0.34
0.36
0.38
0.4
0.38
Book Value per Share
0.64
0.52
0.65
0.76
0.67
0.75
2.43
2.63
2.95
3.42
3.76
4.05
4.31
5.62
Tangible Book Value per Share
0.24
0.35
0.45
0.5
0.49
0.53
-0.21
0.09
0.02
0.53
0.82
0.84
1.07
-6.24
Basic Weighted Avg Shares
23
24
24
24
24
24
26
27
27
27
27
27
27
28
Sales/Revenue/Turnover
14
16
20
23
27
31
49
61
79
97
97
104
110
124
Operating Margin (%)
31.62
27.52
28.44
30.12
30.32
33.29
23.34
29.64
28.85
30.61
27.28
24.2
23.17
14.08
Depreciation Expense
- -
1
1
1
2
1
2
5
4
3
4
5
4
5
Net Income, GAAP
4
-1
6
6
7
8
9
13
17
22
19
18
17
12
Effective Tax Rate (%)
29.71
19.79
22.24
21.54
17.38
20.83
23.87
20.08
21.62
25.13
24.72
24.88
23.72
30.54
Profit Margin (%)
32.11
-4.33
32.08
23.83
25.57
26.43
18.88
21.88
21.99
22.43
19.79
17.87
15.88
9.41
Working Capital
5
5
10
9
11
12
22
26
- -
27
27
25
27
-75
LT Debt
1
1
- -
1
- -
- -
24
22
1
15
12
7
5
7
Total Equity
15
12
15
15
16
18
64
70
78
91
100
108
115
150
Return on Invested Capital (%)
17.22
23.2
30.45
34.98
41.87
46.53
17.02
14.13
17
20.25
16.84
15.62
15.68
8.93
Return on Capital (%)
24.97
-4.38
44.26
35.3
42.77
46.69
17.03
14.25
17.51
20.52
17.17
15.96
14.39
8.54
Return on Common Equity (%)
29.28
-5.09
46.65
35.68
43.17
47.58
22.67
19.93
23.38
25.69
20.03
17.82
15.66
8.95

Capital Structure

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
6
2
3
LT Borrowings
2
- -
- -
LT Finance Leases
4
3
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
27
27
27
Market Capitalization
500
430
272

Working Capital

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
53
51
105
Cash, Cash Equivalents & STI
26
21
18
Accounts Receivable, Net
11
18
43
Inventories
11
11
45
Total Current Liabilities
26
22
181
Payables & Accruals
- -
- -
- -
ST Debt
6
2
3
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
33.65%
10.52%
6.49%
Free Cash Flow
31.92%
41.19%
32.24%
Net Income, GAAP
11.92%
6.8%
-5.87%
Sales/Revenue/Turnover
19.41%
12.97%
5.95%
Total Cash Common Dividend
12.37%
6.01%
5.28%

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
24
25
24
31
104
2025
26
27
- -
31
110
2026
27
39
- -
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.14
0.15
0.16
0.25
0.7
2025
0.16
0.12
- -
0.21
0.65
2026
0.09
0.02
- -
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.38
- -
- -
0.38
2025
- -
0.4
- -
- -
0.4
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jouni Erik Toijala
Full Time Employees
247
Sector
Health technology
Industry
Medical specialties
Address
Härkähaankuja 7 Vantaa UU Finland 01730
IPO Date
Jan 1, 2003
Website
reveniogroup.fi
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Revenio Group Oyj operates as a health technology innovator, developing, producing, and distributing advanced diagnostic tools for eye care professionals worldwide. Its offerings address conditions such as glaucoma, macular degeneration, diabetic retinopathy, and cataracts across European, American, and Asian markets. The firm’s comprehensive iCare product suite features various intraocular pressure measurement devices, including the iCare IC100, IC200, and the iCare HOME2 for personal use, alongside the new iCare ST500 Slit Lamp tonometer. Imaging solutions include the iCare EIDON for true-color confocal retinal scans and the iCare DRSplus for retinal examination. Visual field analysis is provided through instruments like the iCare COMPASS and MAIA. Furthermore, Revenio delivers sophisticated software platforms such as Oculo, facilitating clinical communication, remote monitoring, and data analysis in eye care, and iCare ILLUME, an AI-powered screening tool for early disease detection. Established in 2001, Revenio Group Oyj maintains its headquarters in Vantaa, Finland.